Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 14.868
Filter
1.
J Nippon Med Sch ; 91(3): 285-295, 2024.
Article in English | MEDLINE | ID: mdl-38972741

ABSTRACT

BACKGROUND: The standard treatment for Kawasaki disease is immunoglobulin therapy, but the high frequency of coronary sequelae in immunoglobulin-refractory cases indicates a need for further improvement in treatment. METHODS: Kawasaki disease-like vasculitis was induced in 5-week-old DBA/2 mice by intraperitoneal administration of 0.5 mg Candida albicans water-soluble fraction (CAWS) daily for 5 days followed by daily administration of candesartan, an angiotensin receptor blocker. The vasculitis suppression effect was confirmed histologically and serologically in mice sacrificed at 28 days after the start of candesartan. RESULTS: The area of inflammatory cell infiltration at the aortic root was 2.4±1.4% in the Control group, 18.1±1.9% in the CAWS group, and 7.1±2.3%, 5.8±1.4%, 7.6±2.4%, and 7.9±5.0% in the CAWS+candesartan 0.125-mg/kg, 0.25-mg/kg, 0.5-mg/kg, and 1.0-mg/kg groups, respectively (p=0.0200, p=0.0122, p=0.0122, and p=0.0200 vs. CAWS, respectively). The low-dose candesartan group also showed significantly reduced inflammatory cell infiltration. A similar trend was confirmed by immunostaining of macrophages and TGFß receptors. Measurement of the inflammatory cytokines IL-1ß, IL-6, and TNF-α confirmed the anti-vasculitis effect of candesartan. CONCLUSIONS: Candesartan inhibited vasculitis even at clinical doses used in children, making it a strong future candidate as an additional treatment for immunoglobulin-refractory Kawasaki disease.


Subject(s)
Benzimidazoles , Biphenyl Compounds , Candida albicans , Disease Models, Animal , Mucocutaneous Lymph Node Syndrome , Tetrazoles , Animals , Benzimidazoles/pharmacology , Benzimidazoles/administration & dosage , Mucocutaneous Lymph Node Syndrome/drug therapy , Tetrazoles/pharmacology , Tetrazoles/administration & dosage , Candida albicans/drug effects , Biphenyl Compounds/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Mice, Inbred DBA , Solubility , Water , Vasculitis/drug therapy , Male , Mice , Cytokines/metabolism , Interleukin-6/metabolism
2.
Front Immunol ; 15: 1411979, 2024.
Article in English | MEDLINE | ID: mdl-38989288

ABSTRACT

Background: Kawasaki disease (KD), an acute febrile illness and systemic vasculitis, is the leading cause of acquired heart disease in children in industrialized countries. KD leads to the development of coronary artery aneurysms (CAA) in affected children, which may persist for months and even years after the acute phase of the disease. There is an unmet need to characterize the immune and pathological mechanisms of the long-term complications of KD. Methods: We examined cardiovascular complications in the Lactobacillus casei cell wall extract (LCWE) mouse model of KD-like vasculitis over 4 months. The long-term immune, pathological, and functional changes occurring in cardiovascular lesions were characterized by histological examination, flow cytometric analysis, immunofluorescent staining of cardiovascular tissues, and transthoracic echocardiogram. Results: CAA and abdominal aorta dilations were detected up to 16 weeks following LCWE injection and initiation of acute vasculitis. We observed alterations in the composition of circulating immune cell profiles, such as increased monocyte frequencies in the acute phase of the disease and higher counts of neutrophils. We determined a positive correlation between circulating neutrophil and inflammatory monocyte counts and the severity of cardiovascular lesions early after LCWE injection. LCWE-induced KD-like vasculitis was associated with myocarditis and myocardial dysfunction, characterized by diminished ejection fraction and left ventricular remodeling, which worsened over time. We observed extensive fibrosis within the inflamed cardiac tissue early in the disease and myocardial fibrosis in later stages. Conclusion: Our findings indicate that increased circulating neutrophil counts in the acute phase are a reliable predictor of cardiovascular inflammation severity in LCWE-injected mice. Furthermore, long-term cardiac complications stemming from inflammatory cell infiltrations in the aortic root and coronary arteries, myocardial dysfunction, and myocardial fibrosis persist over long periods and are still detected up to 16 weeks after LCWE injection.


Subject(s)
Cell Wall , Disease Models, Animal , Fibrosis , Lacticaseibacillus casei , Mucocutaneous Lymph Node Syndrome , Vasculitis , Animals , Mice , Cell Wall/immunology , Vasculitis/immunology , Vasculitis/etiology , Vasculitis/pathology , Mucocutaneous Lymph Node Syndrome/immunology , Mucocutaneous Lymph Node Syndrome/complications , Male , Myocarditis/etiology , Myocarditis/pathology , Myocarditis/immunology , Inflammation/immunology
3.
Immunol Allergy Clin North Am ; 44(3): 483-502, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38937011

ABSTRACT

Urticarial vasculitis is a rare autoimmune disorder characterized by persistent edematous papules and plaques on the skin that last longer than 24 hours, often accompanied by systemic symptoms such as joint pain and fever. Unlike common urticaria, this condition involves inflammation of small blood vessels, leading to more severe and long-lasting skin lesions with a tendency to leave a bruiselike appearance. Diagnosis is challenging and may require a skin biopsy. Associated with underlying autoimmune diseases, treatment involves managing symptoms with medications such as antihistamines and corticosteroids, addressing the immune system's dysfunction, and treating any concurrent autoimmune conditions.


Subject(s)
Urticaria , Vasculitis , Humans , Urticaria/diagnosis , Urticaria/etiology , Urticaria/immunology , Vasculitis/diagnosis , Skin/pathology , Skin/immunology , Diagnosis, Differential , Histamine Antagonists/therapeutic use , Autoimmune Diseases/diagnosis , Autoimmune Diseases/immunology , Biopsy , Vasculitis, Leukocytoclastic, Cutaneous/diagnosis , Vasculitis, Leukocytoclastic, Cutaneous/immunology , Vasculitis, Leukocytoclastic, Cutaneous/etiology
6.
Arthritis Res Ther ; 26(1): 123, 2024 Jun 24.
Article in English | MEDLINE | ID: mdl-38915065

ABSTRACT

BACKGROUND: Treatments for rheumatoid arthritis (RA) are associated with complex changes in lipids and lipoproteins that may impact cardiovascular (CV) risk. The objective of this study was to examine lipid and lipoprotein changes associated with two common RA treatment strategies, triple therapy or tumor necrosis factor inhibitor (TNFi), and association with CV risk. METHODS: In this secondary data analysis of the TARGET trial, methotrexate (MTX) inadequate responders with RA were randomized to either add sulfasalazine and hydroxychloroquine (triple therapy), or TNFi for 24-weeks. The primary trial outcome was the change in arterial inflammation measured in the carotid arteries or aorta by FDG-PET/CT at baseline and 24-weeks; this change was described as the target-to-background ratio (TBR) in the most diseased segment (MDS). Routine lipids and advanced lipoproteins were measured at baseline and 24-weeks; subjects on statin therapy at baseline were excluded. Comparisons between baseline and follow-up lipid measurements were performed within and across treatment arms, as well as change in lipids and change in MDS-TBR. RESULTS: We studied 122 participants, 61 in each treatment arm, with median age 57 years, 76% female, and 1.5 year median RA disease duration. When comparing treatment arms, triple therapy had on average a larger reduction in triglycerides (15.9 mg/dL, p = 0.01), total cholesterol to HDL-C ratio (0.29, p-value = 0.01), and LDL particle number (111.2, p = 0.02) compared to TNFi. TNFi had on average a larger increase in HDL particle number (1.6umol/L, p = 0.006). We observed no correlation between change in lipid measurements and change in MDS-TBR within and across treatment arms. CONCLUSIONS: Both treatment strategies were associated with improved lipid profiles via changes in different lipids and lipoproteins. These effects had no correlation with change in CV risk as measured by vascular inflammation by FDG-PET/CT. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT02374021.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Drug Therapy, Combination , Hydroxychloroquine , Lipids , Methotrexate , Humans , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/blood , Female , Middle Aged , Male , Antirheumatic Agents/therapeutic use , Hydroxychloroquine/therapeutic use , Lipids/blood , Methotrexate/therapeutic use , Aged , Sulfasalazine/therapeutic use , Adult , Tumor Necrosis Factor Inhibitors/therapeutic use , Treatment Outcome , Positron Emission Tomography Computed Tomography/methods , Vasculitis/drug therapy , Vasculitis/blood
7.
BMJ Case Rep ; 17(6)2024 Jun 19.
Article in English | MEDLINE | ID: mdl-38901853

ABSTRACT

A man in his 40s with end-stage kidney disease due to IgA nephropathy and receiving peritoneal dialysis presented with a 1-week history of breathlessness, cough and nosebleeds. CT scan of the chest revealed ground glass changes while blood tests indicated elevated inflammatory markers and a negative vasculitis screen. This included negative ANCA and anti-GBM antibodies. Initial treatment for suspected atypical pneumonia with antibiotics yielded no clinical improvement.Over the course of the admission, his symptoms progressively worsened, leading to oxygen dependency with a FiO2 of 40% and episodes of haemoptysis. Suspicions of pulmonary vasculitis arose due to clinical deterioration, prompting consultation with a tertiary vasculitis centre. It was subsequently concluded that the clinical and radiological findings correlated with ANCA-negative pulmonary vasculitis or a rare case of IgA-associated pulmonary capillaritis. Treatment with methylprednisolone and rituximab led to significant improvement, allowing rapid oxygen withdrawal. The patient was discharged with a tapering prednisolone regimen.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic , Humans , Male , Antibodies, Antineutrophil Cytoplasmic/blood , Adult , Rituximab/therapeutic use , Vasculitis/diagnosis , Vasculitis/drug therapy , Methylprednisolone/therapeutic use , Methylprednisolone/administration & dosage , Diagnosis, Differential , Tomography, X-Ray Computed , Kidney Failure, Chronic/complications , Lung Diseases/diagnosis , Lung Diseases/drug therapy , Lung Diseases/diagnostic imaging , Immunoglobulin A/blood
8.
Int Wound J ; 21(6): e14943, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38899689

ABSTRACT

Vasculitic and pyoderma gangrenosum ulcers are traditionally treated with immunosuppressants, and the role of surgery in the treatment of these atypical ulcers remains unclear. This study aimed to investigate the need for surgical intervention as well as the outcome and safety of skin grafting in the treatment of 46 patients with vasculitic ulcers and 34 with pyoderma gangrenosum ulcers using data recorded in the validated Wound Registry. Of the 80 patients with atypical ulcers, 14% (n = 11) were treated surgically; these patients were older (p = 0.039), had lower mobility status (p = 0.002), and more often pulmonary diseases, rheumatoid arthritis, and previous arterial procedures (p = 0.007; p = 0.031; p = 0.031, respectively) than those treated conservatively. Of 181 ulcers, 15% (n = 27) were surgically treated, 78% once and 22% multiple times. During follow-up, 92.3% of both surgically and conservatively treated ulcers with available data healed. Of the surgically treated ulcers, median healing time after first surgical procedure was 96 days, and post-surgical complications were considered mild or unrelated to surgery. Our results suggest that if surgery is indicated, skin grafting is a safe and efficient treatment method provided that multidisciplinary approach is applied.


Subject(s)
Pyoderma Gangrenosum , Skin Transplantation , Wound Healing , Humans , Pyoderma Gangrenosum/surgery , Pyoderma Gangrenosum/therapy , Male , Female , Skin Transplantation/methods , Middle Aged , Aged , Adult , Treatment Outcome , Aged, 80 and over , Retrospective Studies , Skin Ulcer/surgery , Skin Ulcer/therapy , Vasculitis/surgery , Vasculitis/complications
9.
Br J Hosp Med (Lond) ; 85(6): 1-7, 2024 Jun 30.
Article in English | MEDLINE | ID: mdl-38941968

ABSTRACT

Systemic lupus erythematosus (SLE) is a complex autoimmune disease where the body loses tolerance to its own antigens, particularly nuclear antigens. Abnormal responses from T and B cells lead to the production of autoantibodies and the formation of immune complexes in tissues, triggering complement activation, inflammation, and irreversible organ damage. SLE can affect any part of the body, resulting in diverse clinical symptoms. One rare manifestation of SLE is lupus mesenteric vasculitis (LMV), which presents with vague symptoms, abnormal laboratory findings, and specific imaging features. LMV, although uncommon, can progress to severe complications such as bowel perforation, haemorrhage, and even mortality. Here, we report a case of LMV with the involvement of multiple organ systems (including mucocutaneous, musculoskeletal, serosal cavities, and haematological systems), presenting initially with life-threatening intractable gastrointestinal bleeding, and complicated by severe pulmonary infection. By sharing this case, we aim to enhance clinicians' confidence in managing critical SLE cases and raise awareness about disease surveillance.


Subject(s)
Gastrointestinal Hemorrhage , Lupus Erythematosus, Systemic , Vasculitis , Humans , Gastrointestinal Hemorrhage/etiology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Vasculitis/diagnosis , Female , Mesentery , Tomography, X-Ray Computed , Adult
10.
Kaohsiung J Med Sci ; 40(7): 612-620, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38828518

ABSTRACT

Palpable purpura, gastrointestinal symptoms, joint involvement, and renal disease characterize immunoglobulin A vasculitis (IgAV). Renal involvement ranging from mild proteinuria to severe nephritic or nephrotic syndrome highlights the importance of monitoring kidney function in patients with IgAV. Recognizing these key features is crucial for early diagnosis and appropriate management to prevent long-term complications related to kidney disease. However, the pathogenesis of IgAV remains unclear. Disease mechanisms involve various factors, including the interplay of aberrantly glycosylated IgA, anti-endothelial cell antibodies, and neutrophils following infection triggers, which are the main pathogenic mechanisms of IgAV. Insights from cases of IgAV related to Coronavirus disease 2019 have offered additional understanding of the connection between infection and IgAV pathogenesis. This review provides a valuable resource for healthcare professionals and rheumatology researchers seeking a better understanding of the clinical features and pathophysiology of IgAV.


Subject(s)
COVID-19 , Immunoglobulin A , Humans , Immunoglobulin A/immunology , COVID-19/immunology , COVID-19/physiopathology , COVID-19/virology , COVID-19/complications , Vasculitis/immunology , Vasculitis/physiopathology , SARS-CoV-2/immunology , IgA Vasculitis/immunology , IgA Vasculitis/physiopathology , IgA Vasculitis/diagnosis , Autoantibodies/immunology , Neutrophils/immunology
11.
J Emerg Med ; 67(1): e60-e64, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38825530

ABSTRACT

BACKGROUND: Idiopathic carotidynia, also known as transient perivascular inflammation of the carotid artery (TIPIC) syndrome, is a rare, self-limited, clinical-radiologic entity. Over the years, the diagnosis of carotidynia has been controversial, but recent pathologic, radiologic, clinical, and laboratory findings support an inflammatory etiology. CASE REPORT: A 61-year-old woman with a history of hypertension, left lower extremity liposarcoma, and right internal jugular port placement 2 weeks prior with initiation of chemotherapy presented to the emergency department with right neck pain and swelling of the lateral neck and lower face for the past 3 days. Computed tomography-neck with IV contrast revealed marked mural thickening of the right common carotid artery, which can be seen with carotidynia (Fay syndrome and TIPIC syndrome) and vasculitis. The patient had elevated inflammatory markers and was treated clinically for carotidynia with ibuprofen, evaluated by vascular surgery, and discharged home. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: The causes of acute neck pain are diverse, ranging from nonemergent to surgically emergent etiologies. As radiologists and emergency physicians, we believe TIPIC syndrome is a rare entity with important clinical impact deserving attention, as it is not typically included in medical training and is usually learned only through years of clinical experience and practice. TIPIC syndrome requires a unique combination of both clinical and radiologic findings to diagnose accurately and appropriately. It is important to be familiar with this diagnosis because treatment is focused on symptomatic relief without the need for invasive procedures. Our goal was to increase awareness of this uncommon diagnosis to improve patient care by preventing unnecessary invasive procedures and aid in timely and accurate diagnosis.


Subject(s)
Tomography, X-Ray Computed , Humans , Female , Middle Aged , Tomography, X-Ray Computed/methods , Neck Pain/etiology , Carotid Artery Diseases/diagnosis , Carotid Artery Diseases/complications , Ibuprofen/therapeutic use , Inflammation , Emergency Service, Hospital/organization & administration , Vasculitis/complications , Vasculitis/diagnosis , Syndrome
12.
G Ital Nefrol ; 41(3)2024 06 28.
Article in English | MEDLINE | ID: mdl-38943330

ABSTRACT

IgA nephropathy (IgAN) is a fairly common association with alcoholic liver disease. However, IgA vasculitis (IgAV) is quite an uncommon association with alcoholic liver cirrhosis and only a handful of cases have been reported in literature. Secondary IgAN usually presents in a docile manner, progressing slowly in about 5-25 years. It is usually responsive to steroid therapy, very rarely progressing to End-Stage Renal Disease. Here, we present a man in his late 50s, a known hypertensive and alcohol related liver-cirrhotic, who presented to our hospital with rash and rapidly progressive renal failure (RPRF). He was diagnosed with IgA nephritis with IgA vasculitis (IgAVN). His diagnosis was confirmed with skin and renal biopsy. He was started on renal replacement therapy for his renal failure and began oral steroid therapy. After administration of steroid therapy for 6 months, the patient recovered and was dialysis independent with stable renal parameters.


Subject(s)
Glomerulonephritis, IGA , Humans , Male , Glomerulonephritis, IGA/complications , Glomerulonephritis, IGA/diagnosis , Middle Aged , Disease Progression , Liver Diseases, Alcoholic/complications , IgA Vasculitis/complications , IgA Vasculitis/diagnosis , IgA Vasculitis/drug therapy , Vasculitis/complications , Vasculitis/etiology , Vasculitis/diagnosis , Vasculitis/drug therapy
14.
Reumatol Clin (Engl Ed) ; 20(5): 281-285, 2024 May.
Article in English | MEDLINE | ID: mdl-38821739

ABSTRACT

Scurvy is a nutritional disease caused by ascorbic acid (vitamin C) deficiency. Althought currently it is a rare disease, we should considerer it in the differential diagnosis of purpura and arthritis in patients with restrictive diets. We present the case of a 49-year-old man with a history of a nutritional disorder presented to our hospital with generalized purpura and hemarthros. Following the anamnesis and laboratory findings, rheumatological, infectious and hematological etiologies were excluded. Finally, the diagnosis of scurvy was made upon demostration poor levels of vitamin C and a spectacular response to nutritional supplements. We compare this case with 19 similar cases reported in the medical literature.


Subject(s)
Scurvy , Scurvy/diagnosis , Scurvy/complications , Humans , Male , Middle Aged , Diagnosis, Differential , Vasculitis/etiology , Vasculitis/diagnosis , Ascorbic Acid/therapeutic use
15.
Front Immunol ; 15: 1354349, 2024.
Article in English | MEDLINE | ID: mdl-38707895

ABSTRACT

Antiphospholipid antibodies (aPL) are both laboratory evidence and causative factors for a broad spectrum of clinical manifestations of antiphospholipid syndrome (APS), with thrombotic and obstetric events being the most prevalent. Despite the aPL-triggered vasculopathy nature of APS, vasculitic-like manifestations rarely exist in APS and mainly appear associated with other concurrent connective tissue diseases like systemic lupus erythematous. Several studies have characterized pulmonary capillaritis related to pathogenic aPL, suggesting vasculitis as a potential associated non-thrombotic manifestation. Here, we describe a 15-year-old girl who develops hepatic infarction in the presence of highly positive aPL, temporally related to prior non-severe COVID-19 infection. aPL-related hepatic vasculitis, which has not been reported before, contributes to liver ischemic necrosis. Immunosuppression therapy brings about favorable outcomes. Our case together with retrieved literature provides supportive evidence for aPL-related vasculitis, extending the spectrum of vascular changes raised by pathogenic aPL. Differentiation between thrombotic and vasculitic forms of vascular lesions is essential for appropriate therapeutic decision to include additional immunosuppression therapy. We also perform a systematic review to characterize the prevalence and clinical features of new-onset APS and APS relapses after COVID-19 for the first time, indicating the pathogenicity of aPL in a subset of COVID-19 patients.


Subject(s)
Antibodies, Antiphospholipid , Antiphospholipid Syndrome , COVID-19 , SARS-CoV-2 , Vasculitis , Humans , COVID-19/complications , COVID-19/immunology , Female , Adolescent , Antibodies, Antiphospholipid/blood , Antibodies, Antiphospholipid/immunology , Vasculitis/immunology , Vasculitis/etiology , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/immunology , SARS-CoV-2/immunology , Liver/pathology
16.
J Autoimmun ; 146: 103242, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38761452

ABSTRACT

OBJECTIVE: To assess the prognosis and outcome of patients with isolated carotid vasculitis. METHODS: We performed a retrospective multicenter study of 36 patients (median age at diagnosis was 37 [IQR 27-45] years and 11 [31 %] patients were men) with initial presentation as isolated carotid vasculitis. Study endpoints included vascular complications, relapses, and progression to large vessel vasculitis (i.e. Giant cell arteritis or Takayasu). RESULTS: The most frequent involvement was the left internal carotid artery (39 %), and 81 % had stenosis. After a median follow-up of 32 months [IQR 12-96], 21 (58 %) patients had a vascular event, including 31 % of new onset vascular lesions and 25 % of stroke/transient ischemic attack. Patients with stroke had less carotidynia at diagnosis (33 % vs 74 %, p = 0.046), higher significant carotid stenosis (i.e. > 50 %) (89 % vs. 30 %, p = 0.026) and higher severe carotid stenosis (i.e. >70 %) (67 % vs 19 %, p = 0.012), compared to those without stroke. Twenty (52 %) patients experienced relapses. High CRP at diagnosis was associated with relapses (p = 0.022). At the end of follow-up, 21 (58 %) patients were classified as having Takayasu arteritis, 13 (36 %) as isolated carotid vasculitis, and two (6 %) as giant cell arteritis. CONCLUSION: Carotid vasculitis may occur as a topographically limited lesion and is associated with significant rate of vascular complications.


Subject(s)
Giant Cell Arteritis , Humans , Male , Female , Prognosis , Middle Aged , Retrospective Studies , Adult , Giant Cell Arteritis/diagnosis , Takayasu Arteritis/diagnosis , Recurrence , Vasculitis/diagnosis , Follow-Up Studies , Stroke/etiology , Stroke/diagnosis , Carotid Stenosis/diagnosis , Disease Progression
17.
Thromb Res ; 239: 109040, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38795561

ABSTRACT

BACKGROUND AND AIM: Hughes-Stovin syndrome (HSS) is a rare systemic vasculitis with widespread venous/arterial thrombosis and pulmonary vasculitis. Distinguishing between pulmonary embolism (PE) and in-situ thrombosis in the early stages of HSS is challenging. The aim of the study is to compare clinical, laboratory, and computed tomography pulmonary angiography (CTPA) characteristics in patients diagnosed with PE versus those with HSS. METHODS: This retrospective study included 40 HSS patients with complete CTPA studies available, previously published by the HSS study group, and 50 patients diagnosed with PE from a single center. Demographics, clinical and laboratory findings, vascular thrombotic events, were compared between both groups. The CTPA findings were reviewed, with emphasis on the distribution, adherence to the mural wall, pulmonary infarction, ground glass opacification, and intra-alveolar hemorrhage. Pulmonary artery aneurysms (PAAs) in HSS were assessed and classified. RESULTS: The mean age of HSS patients was 35 ± 12.3 years, in PE 58.4 ± 17 (p < 0.0001). Among PE 39(78 %) had co-morbidities, among HSS none. In contrast to PE, in HSS both major venous and arterial thrombotic events are seen.. Various patterns of PAAs were observed in the HSS group, which were entirely absent in PE. Parenchymal hemorrhage was also more frequent in HSS compared to PE (P < 0.001). CONCLUSION: Major vascular thrombosis with arterial aneurysms formation are characteristic of HSS. PE typically appear loosely-adherent and mobile whereas "in-situ thrombosis" seen in HSS is tightly-adherent to the mural wall. Mural wall enhancement and PAAs are distinctive pulmonary findings in HSS. The latter findings have significant therapeutic ramifications.


Subject(s)
Computed Tomography Angiography , Pulmonary Embolism , Humans , Pulmonary Embolism/diagnostic imaging , Female , Male , Adult , Middle Aged , Retrospective Studies , Computed Tomography Angiography/methods , Vasculitis/diagnostic imaging , Vasculitis/complications , Aged , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/pathology
18.
BMJ Case Rep ; 17(5)2024 May 13.
Article in English | MEDLINE | ID: mdl-38740445

ABSTRACT

A woman in her late 30s presented with sudden diminution of vision, redness and pain in the right eye (OD) of 10 days' duration. Best corrected visual acuity (BCVA) was 20/160 in OD and 20/20 in the left eye (OS). Anterior segment of OD showed keratic precipitates, flare 3+, cells 2+ and a festooned pupil. Vitreous haze and cells were seen in OD. Frosted branch angiitis (FBA) was seen in all quadrants in OD and old Toxoplasma scar was seen in both eyes. Serum toxoplasma immunoglobulin G (IgG) was positive and IgM negative, and PCR of an aqueous humour sample was negative for Toxoplasma She was diagnosed with toxoplasa retinochoroiditis in OD and treated with intravitreal clindamycin injections, oral anti-Toxoplasma antibiotics and steroids. Three months later, her BCVA in OD was 20/40 with resolving inflammation. She presented 2 months later with a new focus of retinochoroiditis without FBA and an old Toxoplasma scar.


Subject(s)
Chorioretinitis , Toxoplasma , Toxoplasmosis, Ocular , Humans , Female , Chorioretinitis/drug therapy , Chorioretinitis/diagnosis , Chorioretinitis/parasitology , Toxoplasmosis, Ocular/diagnosis , Toxoplasmosis, Ocular/drug therapy , Toxoplasmosis, Ocular/complications , Toxoplasma/isolation & purification , Adult , Multimodal Imaging , Vasculitis/drug therapy , Vasculitis/diagnosis , Vasculitis/complications , Visual Acuity , Clindamycin/therapeutic use , Clindamycin/administration & dosage , Tomography, Optical Coherence , Anti-Bacterial Agents/therapeutic use
19.
Lupus ; 33(8): 886-891, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38719778

ABSTRACT

In rare instances, patients with SLE may exhibit atypical clinical manifestations, such as Hypocomplementemic Urticarial Vasculitis, which can pose diagnostic challenges. Here, we present a case report of a 28-year-old female with a history of SLE with lupus nephritis clase IV who developed HUV-like symptoms, ultimately leading to a diagnosis of C1q Vasculitis. This case underscores the importance of considering C1q Vasculitis in SLE patients presenting with HUV-like features and highlights Rituximab as a promising therapeutic option for managing this rare condition.


Subject(s)
Complement C1q , Lupus Erythematosus, Systemic , Rituximab , Urticaria , Vasculitis , Humans , Female , Adult , Complement C1q/deficiency , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Vasculitis/diagnosis , Vasculitis/drug therapy , Urticaria/diagnosis , Rituximab/therapeutic use , Lupus Nephritis/diagnosis , Lupus Nephritis/complications , Lupus Nephritis/drug therapy , Diagnosis, Differential
SELECTION OF CITATIONS
SEARCH DETAIL